~~<i id='EE36389CAB'><strike id='EE36389CAB'><tt id='EE36389CAB'><pre id='EE36389CAB'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-09-29 03:50:06 Page View：7165

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： AstraZeneca to buy developer of next
Next article： The high cost of giving birth even with insurance

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

KayanaSzymczakforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiote

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Future doctors should be trained to promote social change

APStockManyAmericansbelievethatwehavethebesthealthcaresystemintheworld.Yetthatdoesn’tsquarewiththefa